Last updated: 5 June 2024 at 5:12pm EST

Francis Patrick Ostronic Net Worth




The estimated Net Worth of Francis Patrick Ostronic is at least $147 Thousand dollars as of 20 April 2023. Francis Ostronic owns over 59,881 units of Cyclo Therapeutics stock worth over $146,765 and over the last 4 years Francis sold CYTH stock worth over $0.

Francis Ostronic CYTH stock SEC Form 4 insiders trading

Francis has made over 18 trades of the Cyclo Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Francis bought 59,881 units of CYTH stock worth $42,516 on 20 April 2023.

The largest trade Francis's ever made was buying 59,881 units of Cyclo Therapeutics stock on 20 April 2023 worth over $42,516. On average, Francis trades about 4,545 units every 25 days since 2020. As of 20 April 2023 Francis still owns at least 222,371 units of Cyclo Therapeutics stock.

You can see the complete history of Francis Ostronic stock trades at the bottom of the page.



What's Francis Ostronic's mailing address?

Francis's mailing address filed with the SEC is C/O CYCLO THERAPEUTICS, INC., 6714 NW 16TH STREET, SUITE B, GAINESVILLE, FL, 32163.

Insiders trading at Cyclo Therapeutics

Over the last 4 years, insiders at Cyclo Therapeutics have traded over $0 worth of Cyclo Therapeutics stock and bought 4,648,141 units worth $6,142,223 . The most active insiders traders include Holdings, Inc. Rafael, Shawn Cross, and N Scott Fine. On average, Cyclo Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $78,661. The most recent stock trade was executed by Holdings, Inc. Rafael on 1 August 2023, trading 4,000,000 units of CYTH stock currently worth $5,000,000.



What does Cyclo Therapeutics do?

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.



Complete history of Francis Ostronic stock trades at Cyclo Therapeutics

Insider
Trans.
Transaction
Total value
Francis Patrick Ostronic
Director
Buy $42,516
20 Apr 2023
Francis Patrick Ostronic
Director
Buy $8,800
21 Sep 2022
Francis Patrick Ostronic
Director
Buy $10,200
20 May 2022
Francis Patrick Ostronic
Director
Buy $7,500
24 Jan 2022
Francis Patrick Ostronic
Director
Buy $4,528
19 Jan 2022
Francis Patrick Ostronic
Director
Buy $6,924
14 Jan 2022
Francis Patrick Ostronic
Director
Buy $8,548
14 Jan 2022
Francis Patrick Ostronic
Director
Buy $11,700
15 Dec 2021
Francis Patrick Ostronic
Director
Buy $22,000
10 Dec 2021
Francis Patrick Ostronic
Director
Buy $4,104
3 Dec 2021
Francis Patrick Ostronic
Director
Buy $19,646
2 Dec 2021
Francis Patrick Ostronic
Director
Buy $25,000
1 Dec 2021
Francis Patrick Ostronic
Director
Buy $55,923
19 Nov 2021
Francis Patrick Ostronic
Director
Buy $5,900
29 Oct 2021
Francis Patrick Ostronic
Director
Buy $65,300
16 Apr 2021
Francis Patrick Ostronic
Director
Buy $35,000
12 Apr 2021
Francis Patrick Ostronic
Director
Buy $22,590
29 Mar 2021
Francis Patrick Ostronic
Director
Buy $139,800
17 Dec 2020


Cyclo Therapeutics executives and stock owners

Cyclo Therapeutics executives and other stock owners filed with the SEC include: